Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCHID: Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Breast Cancer
NCT04296162Phase 2Completed
- Sponsor
- Fudan University
- Start
- Mar 2020
- Primary completion
- Apr 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vinorelbine, capecitabine in breast cancer, sponsored by Fudan University. Started Mar 2020; status: completed.
02
Drugs
vinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04296162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296162.